NUSNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends December 31

NU SKIN ENTERPRISES, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$4.97−0.17 (-3.31%)

Close on Oct 19, 2026

Market cap: $241.52M
P/E (TTM): –
Dividend yield: –

NU SKIN ENTERPRISES, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31
Revenue	1,485	1,732	1,969	2,226	2,696	2,582	2,420	2,679	2,279	2,208	2,247	2,569	3,177	2,132	1,720	1,537	1,331	–
Cost of Revenue	454	550	612	631	675	658	581	634	502	500	490	478	506	353	323	272	244	229
Gross Profit	1,031	1,182	1,357	1,595	2,020	1,924	1,839	2,045	1,777	1,707	1,758	2,091	2,671	1,779	1,397	1,265	1,087	1,019
Research & Development	11	13	23	23	27	23	30	23	22	24	20	19	18	15	14	12	10	–
General & Administrative	432	479	547	556	654	636	616	662	565	554	561	622	640	505	436	401	369	360
Advertising Expenses	–	–	–	–	–	15	16	19	16	16	11	20	11	5.10	2.30	2.10	2.00	–
Operating Expenses	966	1,333	1,309	1,484	1,786	1,666	1,572	1,804	1,503	1,476	1,513	1,739	2,117	1,438	1,163	1,048	940	894
Operating Income	66	-152	48	111	234	258	267	241	274	231	245	352	554	341	234	217	148	125
Interest Expense	14	26	26	13	11	13	19	22	22	16	7.90	5.70	3.00	5.20	4.80	5.80	6.90	–
Income from Equity Investments	–	–	–	–	–	0	0	0.46	1.05	0	0	–	–	–	–	–	–	–
Other Non-Operating Income	-32	2.94	3.87	-8.38	-1.53	-1.33	-12	-21	-8.92	-18	-33	-54	2.83	4.40	-6.97	-9.45	-6.59	-25
Merger & Restructuring Charges	25	202	20	48	52	0	0	22	0	0	–	–	–	–	0	0	11	0
Asset Impairment Charges	25	181	0	9.92	32	0	0	0	0	0	0	0	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	-0.16	0.08	-0.78	-0.03	-13	-3.21	0	0	–	–	–	–	–	–	–	–	–	–
Pretax Income	196	-175	27	89	232	256	255	220	266	213	212	299	557	345	227	208	141	101
Income Tax Expense	36	-28	18	-16	85	65	82	98	136	70	79	109	192	124	73	72	51	35
Net Income	160	-147	8.60	105	147	191	174	122	129	143	133	189	365	222	153	136	90	65
EPS (Basic)(per share)	3.25	-2.95	0.17	2.10	2.93	3.66	3.13	2.21	2.45	2.58	2.29	3.20	6.23	3.66	2.47	2.18	1.42	1.03
EPS (Diluted)(per share)	3.18	-2.95	0.17	2.07	2.86	3.63	3.10	2.16	2.36	2.55	2.25	3.11	5.94	3.52	2.38	2.11	1.40	1.02
Shares Outstanding (Basic, Weighted)(shares)	49	50	50	50	50	52	56	55	53	55	58	59	59	61	62	62	63	64
Shares Outstanding (Diluted, Weighted)(shares)	50	50	50	51	51	53	56	56	55	56	59	61	61	63	65	65	64	64
Dividend per Share(per share)	–	–	–	–	–	–	–	–	–	–	0.35	0.35	0.30	0.20	0.16	0.13	–	–
EBITDA	118	-82	119	183	310	332	344	324	346	304	316	407	589	374	267	247	176	156

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 69.2%
Operating margin: -0.8%
Net margin: -15.7%
Return on equity, FY2025: 22.0%

Financial strength

Current ratio: 1.98
Debt to equity: 0.39
Debt to assets: 19.1%
Cash to current liabilities: 74.0%

Valuation

P/E ratio: –
Price to sales: 0.18
Price to book: 0.45
Dividend yield: –